Brand name: Simvastatin (AN)
Simvastatin (AN) is a medicine containing the active ingredient(s) simvastatin. On this page you will find out more about Simvastatin (AN), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: simvastatin
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Simvastatin (AN) 10 mg film-coated tablet, 30
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Adjunct to diet for treatment of hypercholesterolaemia. Prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. Simvastatin is indicated in patients at high risk of coronary heart disease (CHD) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance |
Light pink coloured, round shaped, biconvex, film coated tablets, debossed with 'A' on one side and '01' on the other side
Images are the copyright of the Pharmacy Guild of Australia |
| Dosage Form | Tablet, film coated |
| Route of administration | Oral |
| Medicine schedule |
30 Tablets: Prescription Only Medicine, or Prescription Animal Remedy
|
There is one type of pack available.
Pack type 1
| Type | Blister Pack |
|---|---|
| Storage temperature | Store below 25 degrees Celsius |
| Storage conditions | No information available |
| Life time | 3 Years |
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 October 2017
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 162 results
Simvastatin AN Tablets - myDr.com.au
Simvastatin AN Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Simvastatin Winthrop Tablets - myDr.com.au
Simvastatin Winthrop Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Simvastatin Sandoz Tablets - myDr.com.au
Simvastatin Sandoz Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Chemmart Simvastatin Tablets - myDr.com.au
Chemmart Simvastatin Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
APO-Simvastatin Tablets - myDr.com.au
APO-Simvastatin Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Terry White Chemists Simvastatin Tablets - myDr.com.au
Terry White Chemists Simvastatin Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Simvastatin-Spirit Tablets - myDr.com.au
Simvastatin-Spirit Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Synthon Simvastatin Tablets - myDr.com.au
Synthon Simvastatin Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Simvastatin Generichealth Tablets - myDr.com.au
Simvastatin Generichealth Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Simvastatin-DRLA Tablets - myDr.com.au
Simvastatin-DRLA Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 14 results
There good evidence that statins given in late life to individuals at risk of vascular disease have no effect in preventing dementia | Cochrane
Read more on Cochrane (Australasian Centre) website
Statins for the treatment of Alzheimer's disease | Cochrane
High levels of cholesterol (a fatty substance known as a lipid) in the blood are thought to contribute to the cause of Alzheimer's disease and vascular dementia. The statin family of medications (lovastatin, pravastatin, simvastatin and others) are powerful cholesterol-lowering medications and are first-line treatments for reducing cholesterol in people with, or at risk of, cardiovascular disease. There has been much interest in the possible role of statins in the treatment of dementia.
Read more on Cochrane (Australasian Centre) website
Statins for non-alcoholic steatohepatitis | Cochrane
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in patients with no or very little alcohol consumption is characterised by hepatic histological changes similar to those associated with alcohol-induced liver injury. A range of histological changes can be seen. Some patients have fat accumulation in hepatocytes without significant inflammation or fibrosis (simple hepatic steatosis or NAFLD), but others have hepatic steatosis with prominent necro-inflammatory changes with or without associated fibrosis (this is NASH). Although NAFLD and NASH are common conditions, no effective medical treatment is available to correct the abnormal liver enzymes and adverse outcomes associated with them. This systematic review identified two randomised clinical trials with very small numbers of participants. One of the trials was a pilot trial and compared simvastatin with placebo, and the other trial assessed atorvastatin versus fenofibrate versus a combination of the two. The small pilot trial (n = 16 patients) assessing simvastatin versus placebo in NASH patients did not show significant effects on liver enzyme activities or liver histology. No adverse events were reported. The other trial compared atorvastatin versus fenofibrate versus a group receiving both interventions in 186 patients with NAFLD. There were no statistically significant differences between any of the three intervention groups regarding the 54 week mean activities of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, or alkaline phosphatases (liver enzymes) in the blood. The triglyceride levels seemed higher in the fenofibrate group compared with the atorvastatin group. Liver histology was not assessed in this trial. The presence of biochemical and ultrasonographic evidence of NAFLD seemed higher in the fenofibrate group compared with the other two intervention groups. Three patients discontinued treatment due to myalgia and elevated serum creatine kinase activity, one from the atorvastatin group and two from the combination group. Another patient from the atorvastatin group discontinued treatment due to raised alanine aminotransferase activity, over three times the upper normal limit. Both trials were at high risk of bias (that is, overestimation of benefits and underestimation of harms). Furthermore, the groups were small raising the risks of random errors (that is, play of chance). Accordingly, we did not find evidence to support or refute the use of statins for patients with NAFLD or NASH. Further unbiased trials with larger numbers of patients looking explicitly at patient-related outcomes of interest (for example, quality of life, development of cirrhosis, and mortality) are needed to assess the effects of statins on NAFLD or NASH.
Read more on Cochrane (Australasian Centre) website
Statins for acute coronary syndrome | Cochrane
Long-term therapy with statins (for at least one year) has been shown to reduce the risk of heart attack, stroke, and all-cause mortality in patients with and without established coronary heart disease. The early period following an acute coronary syndrome is a critical stage of coronary heart disease, with a high risk of recurrent events and death. We aimed to determine if early initiation of statins improves patient-relevant outcomes within the first four months following an acute coronary syndrome. This review is an update of a review previously published in 2011 that included 18 studies, enrolling 14,303 patients. The update of this review did not identify any new studies for inclusion. We did not find a significant risk reduction for all-cause mortality, heart attack, or stroke within the first four months. We had some concerns about risk of bias and imprecision of the results. The risk of unstable angina was reduced by about 25% at four months following acute coronary syndrome. Serious side effects from early treatment with statins were rare (0.1%), and serious muscle toxicity was mostly observed with simvastatin 80 mg.
Read more on Cochrane (Australasian Centre) website
The use of Statins, cholesterol lowering agents, in patients with multiple sclerosis (MS) | Cochrane
MS is an inflammatory demyelinating disease of the human central nervous system and it is thought to be related to abnormal working of the immune system. Preliminary studies have shown thatstatins, cholesterol lowering agents, have potential immunological regulation effects which may be beneficial for MS. Furthermore, statins are usually orally administered, are less expensive than other MS treatment, and are easily available.
Read more on Cochrane (Australasian Centre) website
Lipid-lowering agents for nephrotic syndrome | Cochrane
Nephrotic syndrome is a relatively rare disease in which the kidneys leak protein into the urine. A common early sign is swelling in the feet and face. Other signs and symptoms of nephrotic syndrome include low levels of protein in the blood, and high levels of fats in the blood, particularly cholesterol and triglycerides.
Read more on Cochrane (Australasian Centre) website
Statins for delaying the onset and progression of age-related macular degeneration | Cochrane
Read more on Cochrane (Australasian Centre) website
Lipid-lowering for peripheral arterial disease of the lower limb | Cochrane
Atheroma (fatty deposits) in the walls of the arteries to the legs can lead to peripheral arterial disease with insufficient blood flow to the muscles and other tissues. People with peripheral arterial disease often do not have symptoms. The most common symptom is intermittent claudication, which is characterised by leg pain and weakness brought on by walking, with disappearance of the symptoms following a brief rest. Lipid-lowering therapies may reduce cardiovascular events and worsening of local disease for people with lower limb peripheral arterial disease. They are recommended to people with coronary artery disease, for prevention of myocardial infarction and stroke.
Read more on Cochrane (Australasian Centre) website
Medications for cognitive decline in people with Down syndrome | Cochrane
People with Down syndrome often experience cognitive decline (a deterioration in memory, language, thinking and judgment that are greater than normal age-related changes) at a younger age and in greater numbers than the general population. Various medicines have been shown to improve, or at least slow down the progression of these symptoms in people without Down syndrome.
Read more on Cochrane (Australasian Centre) website
Lipid lowering in renal disease | Issue 4 | Volume 40 | Australian Prescriber | Australian Prescriber
Statins reduce the risk of cardiovascular disease in patients with chronic kidney disease who do not require...
Read more on Australian Prescriber website
